Intravacc and Primrose Bio Announce Partnership to Enhance Conjugate Vaccine Development
28. März 2024 03:00 ET
|
Intravacc B.V.
Primrose Bio will supply its industry-leading carrier protein, PeliCRM197®, for vaccine developmentIntravacc has IP and know-how in vaccine conjugation and manufacturing of carrier protein based...
Intravacc announces positive data of first in human intranasal OMV based vaccine for SARS-CoV-2
26. März 2024 03:00 ET
|
Intravacc B.V.
First in human phase I clinical study using OMV as an adjuvant for intranasal vaccinationAvacc 10® intranasal booster vaccine induces a mucosal response and no adverse eventsData will be presented at...
Intravacc Awarded US$ 633K CARB-X Funding to Develop a Vaccine that Prevents Gonorrhea Infections
16. Januar 2024 06:00 ET
|
Intravacc B.V.
Intravacc secures $633K funding from CARB-X to develop a vaccine against or Neisseria gonorrhoeae.
Intravacc launches new website with a wealth of scientific knowledge to elevate vaccine innovation
20. Dezember 2023 06:10 ET
|
Intravacc B.V.
Intravacc's new website offers an immersive user experience, showcasing their CDMO expertise vaccine platforms and a hub for scientific publications.
Intravacc announces publication of In Vitro alternative to replace animal pyrogen test for vaccines
19. September 2023 02:00 ET
|
Intravacc B.V.
Intravacc and Sanquin Diagnostic Services optimized the in vitro Monocyte Activation Test (MAT) for OMV vaccinesMAT test potential replacement for the traditional rabbit pyrogen testing (RPT) for...
Intravacc Announces Review Publication of OMV-based Intranasal Vaccines for Disease Prevention
14. September 2023 02:00 ET
|
Intravacc B.V.
Mucosal route induces both localized and systemic immunityIntravacc is currently developing 3 OMV-based intranasal vaccinesArticle published in peer-reviewed journal ‘Current Opinions in Immunology’ ...